AFM
ATRS

Anson Funds Management’s Antares Pharma, Inc. ATRS Stock Holding History

Anson Funds Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-265,425
Closed -$321K – 92
2015
Q4 		$321K Buy
+265,425
New +$369K 0.1% 62

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WHI
William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Anson Funds Management's ATRS Position: Q1 2016 in Review

Anson Funds Management sold out of Antares Pharma, Inc. (ATRS) in Q1 2016, closing a stake of 265,425 shares — an estimated $321K sold.

Anson Funds Management first reported a position in ATRS in Q4 2015 and held it in 1 quarter. The position peaked at $321K in Q4 2015. 83 funds tracked by Wall St. Rank hold ATRS as of Q1 2016.

  • Anson Funds Management reported no remaining Antares Pharma, Inc. position as of Q1 2016 after selling out during the quarter.
  • Anson Funds Management sold 265,425 Antares Pharma, Inc. shares in Q1 2016, an estimated $321K.
  • Anson Funds Management first reported a position in Antares Pharma, Inc. in Q4 2015 and held it in 1 quarter.
  • Anson Funds Management's Antares Pharma, Inc. position peaked at $321K in Q4 2015.
  • 83 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2016.

Based on Anson Funds Management's 13F filing for Q1 2016, filed 13 May 2016.